Clearmind enrolls first AUD patients in CMND-100 trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
September 11, 2026 8:00 AM EDTVancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the Company), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (AUD), today announced the enrollment of the first patients with Alcohol Use Disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the Companys proprietary psychedelic-based treatment candidate for AUD.
The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first time CMND-100 is administered to a patient with AUD. To date, the Company has evaluated... More
